Theravance Biopharma Inc Net Assets
Theravance Biopharma Inc net assets. Based on the latest financial reports, Theravance Biopharma Inc (TBPH) has net assets worth $296.72 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($485.57 Million) and total liabilities ($188.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore TBPH shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $296.72 Million |
| % of Total Assets | 61.11% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -15.28% |
| Growth Volatility | 66.09 |
Net Assets of Theravance Biopharma Inc (2011–2025)
Net assets of Theravance Biopharma Inc from 2011 to 2025. This chart illustrates how Theravance Biopharma Inc's net assets have evolved over time, based on quarterly financial data. See Theravance Biopharma Inc balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for Theravance Biopharma Inc (2011–2025)
The table below shows the annual net assets of Theravance Biopharma Inc from 2011 to 2025. For live market cap and overall valuation, see how much is Theravance Biopharma Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $296.72 Million | +69.03% |
| 2024-12-31 | $175.54 Million | -17.58% |
| 2023-12-31 | $213.00 Million | -51.79% |
| 2022-12-31 | $441.80 Million | +230.49% |
| 2021-12-31 | $-338.57 Million | -11.46% |
| 2020-12-31 | $-303.75 Million | -35.70% |
| 2019-12-31 | $-223.84 Million | -333.89% |
| 2018-12-31 | $-51.59 Million | -144.79% |
| 2017-12-31 | $115.18 Million | -67.11% |
| 2016-12-31 | $350.23 Million | +44.09% |
| 2015-12-31 | $243.06 Million | -16.12% |
| 2014-12-31 | $289.79 Million | +1801.13% |
| 2013-12-31 | $-17.04 Million | -896.20% |
| 2012-12-31 | $-1.71 Million | +98.78% |
| 2011-12-31 | $-140.72 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Theravance Biopharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 71890300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Theravance Biopharma Inc Net Assets Breakdown (December 2025)
Theravance Biopharma Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $61.00K | 0.02% |
| Other Components | $1.16 Billion | 389.69% |
| Total Equity | $296.72 Million | 100.00% |
Theravance Biopharma Inc Competitors by Market Cap
The table below lists competitors of Theravance Biopharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Asia Pacific Light Alloy Technology Co Ltd
SHE:002540
|
$854.99 Million |
|
Jiangxi Guotai Civilian
SHG:603977
|
$855.44 Million |
|
Aarti Pharmalabs Limited
NSE:AARTIPHARM
|
$855.52 Million |
|
Whirlpool China Co Ltd
SHG:600983
|
$855.74 Million |
|
Indus Holding AG
XETRA:INH
|
$854.67 Million |
|
Cisen Pharmaceutical Co Ltd
SHG:603367
|
$854.65 Million |
|
Kayne Anderson BDC, Inc.
NYSE:KBDC
|
$854.59 Million |
|
Dios Fastigheter AB
ST:DIOS
|
$854.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Theravance Biopharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 175,545,000 to 296,723,000, a change of 121,178,000 (69.0%).
- Net income of 105,895,000 contributed positively to equity growth.
- Share repurchases of 4,034,000 reduced equity.
- New share issuances of 20,000 increased equity.
- Other comprehensive income increased equity by 54,000.
- Other factors increased equity by 19,243,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $105.89 Million | +35.69% |
| Share Repurchases | $4.03 Million | -1.36% |
| Share Issuances | $20.00K | +0.01% |
| Other Comprehensive Income | $54.00K | +0.02% |
| Other Changes | $19.24 Million | +6.49% |
| Total Change | $- | 69.03% |
Book Value vs Market Value Analysis
This analysis compares Theravance Biopharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.96x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-4.41 | $17.03 | x |
| 2012-12-31 | $-0.22 | $17.03 | x |
| 2013-12-31 | $-0.53 | $17.03 | x |
| 2014-12-31 | $9.13 | $17.03 | x |
| 2015-12-31 | $7.12 | $17.03 | x |
| 2016-12-31 | $7.83 | $17.03 | x |
| 2017-12-31 | $2.20 | $17.03 | x |
| 2018-12-31 | $-0.96 | $17.03 | x |
| 2019-12-31 | $-4.03 | $17.03 | x |
| 2020-12-31 | $-4.87 | $17.03 | x |
| 2021-12-31 | $-4.87 | $17.03 | x |
| 2022-12-31 | $6.00 | $17.03 | x |
| 2023-12-31 | $3.85 | $17.03 | x |
| 2024-12-31 | $3.59 | $17.03 | x |
| 2025-12-31 | $5.76 | $17.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Theravance Biopharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 35.69%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 98.54%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.64x
- Recent ROE (35.69%) is above the historical average (-18.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -736.06% | 1.07x | 0.00x | $-95.26 Million |
| 2012 | 0.00% | -7.36% | 6.21x | 0.00x | $-8.88 Million |
| 2013 | 0.00% | -69152.21% | 0.01x | 0.00x | $-154.58 Million |
| 2014 | -81.80% | -2028.05% | 0.03x | 1.17x | $-266.02 Million |
| 2015 | -74.97% | -432.56% | 0.14x | 1.23x | $-206.53 Million |
| 2016 | -54.44% | -391.94% | 0.08x | 1.83x | $-225.69 Million |
| 2017 | -247.79% | -1854.97% | 0.03x | 3.83x | $-296.92 Million |
| 2018 | 0.00% | -357.01% | 0.11x | 0.00x | $-210.37 Million |
| 2019 | 0.00% | -322.08% | 0.18x | 0.00x | $-214.07 Million |
| 2020 | 0.00% | -386.90% | 0.15x | 0.00x | $-247.64 Million |
| 2021 | 0.00% | -360.55% | 0.15x | 0.00x | $-165.57 Million |
| 2022 | 197.40% | 1698.54% | 0.08x | 1.37x | $827.95 Million |
| 2023 | -25.91% | -96.11% | 0.15x | 1.79x | $-76.49 Million |
| 2024 | -32.14% | -87.63% | 0.18x | 2.02x | $-73.97 Million |
| 2025 | 35.69% | 98.54% | 0.22x | 1.64x | $76.22 Million |
Industry Comparison
This section compares Theravance Biopharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Theravance Biopharma Inc (TBPH) | $296.72 Million | 0.00% | 0.64x | $854.78 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic n… Read more